ST. LOUIS, Feb. 16, 2017 /PRNewswire/ -- Express Scripts ESRX was recognized today by Fortune Magazine as one of the World's Most Admired Companies within the Health Care: Pharmacy and Other Services category.
"Express Scripts is honored to be named one of the World's Most Admired Companies," said Tim Wentworth, CEO and President, Express Scripts. "This recognition is driven by the commitment and passion of our 26,000 employees to make medicine more affordable and accessible for the 85 million people we serve."
In partnership with the Hay Group, Fortune's World's Most Admired Companies list is based on surveys from 680 companies across 28 countries. To establish the rankings, company executives, board directors and outside analysts were asked to rate companies on nine criteria, including innovation, social responsibility and quality of products and services.
About Express Scripts
Express Scripts puts medicine within reach of tens of millions of people by aligning with plan sponsors, taking bold action and delivering patient-centered care to make better health more affordable and accessible.
Headquartered in St. Louis, Express Scripts provides integrated pharmacy benefit management services, including network-pharmacy claims processing, home delivery pharmacy care, specialty pharmacy care, specialty benefit management, benefit-design consultation, drug utilization review, formulary management, and medical and drug data analysis services. Express Scripts also distributes a full range of biopharmaceutical products and provides extensive cost-management and patient-care services.
For more information, visit Lab.Express-Scripts.com or follow @ExpressScripts on Twitter.
Media Contact:
Ellen Drazen, Express Scripts
314-684-5355
evdrazen@express-scripts.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/express-scripts-named-one-of-fortune-magazines-worlds-most-admired-companies-of-2017-300409135.html
SOURCE Express Scripts
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
